<DOC>
	<DOCNO>NCT00107393</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving trastuzumab together capecitabine may kill tumor cell . PURPOSE : This phase II trial study well give trastuzumab together capecitabine work treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Trastuzumab Capecitabine Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine median survival time 2-year survival rate woman taxane- anthracycline-refractory HER2/neu-overexpressing metastatic breast cancer treat trastuzumab ( Herceptin® ) capecitabine . Secondary - Determine progression-free survival patient treat regimen . - Determine response rate patient treat regimen . - Determine clinical benefit rate regimen patient . - Determine safety profile regimen patient . OUTLINE : This multicenter study . Patients stratify accord prior treatment trastuzumab ( Herceptin® ) ( yes v ) , HER2/neu status ( 3+ immunohistochemistry v positive fluorescence situ hybridization ) , class refractory disease ( primary v secondary v treatment discontinuation due adverse event ) . Patients receive oral capecitabine daily day 1-21 trastuzumab IV day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 2 year . PROJECTED ACCRUAL : A total 75 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Metastatic disease Patients bone metastasis eligible Refractory disease , define disease progression , drugrelated adverse reaction , disease relapse within 12 month completion paclitaxel docetaxel AND doxorubicin epirubicin administer neoadjuvant , adjuvant , metastatic setting Total neoadjuvant adjuvant taxane dose &gt; 700 mg/m^2 paclitaxel &gt; 240 mg/m^2 docetaxel Total taxane dose &gt; 350 mg/m^2 paclitaxel &gt; 120 mg/m^2 docetaxel metastatic setting Total neoadjuvant adjuvant anthracycline dose &gt; 240 mg/m^2 doxorubicin epirubicin Total anthracycline dose &gt; 120 mg/m^2 doxorubicin epirubicin metastatic set HER2/neu overexpression 3+ immunohistochemistry positive fluorescence situ hybridization No symptomatic brain metastases No pleural pericardial effusion ascites Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 20 75 Sex Female Menopausal status Not specify Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic SGOT SGPT ≤ 2.0 time upper limit normal ( ULN ) ( &lt; 3.0 time ULN patient liver metastasis ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 1.5 mg/dL Renal Creatinine ≤ 1.2 mg/dL Cardiovascular LVEF &gt; 50 % Pulmonary No interstitial pneumonia pulmonary fibrosis Other No history hypersensitivity reactions No serious , uncontrolled infection No malignancy Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy Prior trastuzumab ( Herceptin® ) metastatic disease allow Chemotherapy See Disease Characteristics No prior capecitabine At least 2 week since prior antimetabolite metastatic disease At least 4 week since prior alkylating agent , carcinostatic antibiotic , carcinostatic agent Endocrine therapy At least 4 week since prior goserelin leuprolide metastatic disease At least 2 week since prior oral endocrine agent metastatic disease No concurrent endocrine therapy Radiotherapy No prior radiotherapy target lesion At least 4 week since prior radiotherapy No concurrent radiotherapy , include radiotherapy brain metastasis Surgery Not specify Other Concurrent bisphosphonates bone metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>